MX343326B - Metodos para mejorar el metabolismo energetico. - Google Patents

Metodos para mejorar el metabolismo energetico.

Info

Publication number
MX343326B
MX343326B MX2011001733A MX2011001733A MX343326B MX 343326 B MX343326 B MX 343326B MX 2011001733 A MX2011001733 A MX 2011001733A MX 2011001733 A MX2011001733 A MX 2011001733A MX 343326 B MX343326 B MX 343326B
Authority
MX
Mexico
Prior art keywords
energy metabolism
methods
animals
enhancing energy
decline
Prior art date
Application number
MX2011001733A
Other languages
English (en)
Other versions
MX2011001733A (es
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2011001733A publication Critical patent/MX2011001733A/es
Publication of MX343326B publication Critical patent/MX343326B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a isoflavonas de soya para usarse en la elaboración de una composición para incrementar el metabolismo energético en un canino en necesidad del mismo, indicado como un canino sano para quien lo necesita o para quien se dese el incremento del metabolismo energético, en donde la composición está adaptada para ser administrable al canino por vía oral. Las isoflavonas son administrables al canino en cantidades de 0.001 a 10 g/kg/día.
MX2011001733A 2008-08-15 2009-08-10 Metodos para mejorar el metabolismo energetico. MX343326B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903608P 2008-08-15 2008-08-15
PCT/US2009/004584 WO2010019212A2 (en) 2008-08-15 2009-08-10 Methods for enhancing energy metabolism

Publications (2)

Publication Number Publication Date
MX2011001733A MX2011001733A (es) 2011-04-11
MX343326B true MX343326B (es) 2016-11-01

Family

ID=41669526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001733A MX343326B (es) 2008-08-15 2009-08-10 Metodos para mejorar el metabolismo energetico.

Country Status (11)

Country Link
US (1) US8835490B2 (es)
EP (1) EP2320889A4 (es)
JP (1) JP2012504554A (es)
CN (1) CN102300569A (es)
AU (1) AU2009282482B2 (es)
BR (1) BRPI0917866A2 (es)
CA (1) CA2733907C (es)
MX (1) MX343326B (es)
RU (1) RU2513133C2 (es)
WO (1) WO2010019212A2 (es)
ZA (1) ZA201101934B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
CA2833547A1 (en) * 2011-04-20 2012-10-26 Nestec S.A. Methods and compositions suitable for preventing and treating hyperleptinemia
JP6158801B2 (ja) 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2014031836A1 (en) 2012-08-23 2014-02-27 Nestec Sa Managing weight loss and body mass
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
JP6581902B2 (ja) 2013-04-26 2019-09-25 松谷化学工業株式会社 エネルギー消費の促進および／またはエネルギー消費機能低下の治療および／または予防剤、または方法
ES2617035T3 (es) * 2013-06-28 2017-06-15 Nestec S.A. Composiciones y métodos para aumentar el rendimiento deportivo
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
AU2018332181B2 (en) * 2017-09-12 2023-06-29 Societe Des Produits Nestle S.A. Methods for mimicking chronic caloric restriction and for imparting health benefits to an animal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
AU770075B2 (en) * 1999-02-24 2004-02-12 Mars, Incorporated Dietary compositions and methods
US6524616B1 (en) * 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
WO2002004437A1 (fr) * 2000-07-07 2002-01-17 Nichimo Co., Ltd. Matieres inhibitrices de l'obesite
JP2002020304A (ja) * 2000-07-07 2002-01-23 Fancl Corp 食品組成物
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
WO2004039327A2 (en) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
EP2208422B1 (en) * 2004-03-17 2015-11-25 Nestec S.A. Compositions and methods for reducing or preventing obesity
BRPI0510967A (pt) * 2004-05-10 2007-11-20 Itesm inibição do crescimento de células cancerìgenas por extratos de feijão preto (phaseolus vulgaris l)
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
JP2009514824A (ja) * 2005-11-02 2009-04-09 ネステク ソシエテ アノニム 雄の哺乳動物における体脂肪の蓄積を低減するためのイソフラボン組成物及びその使用方法
CA2640575C (en) * 2006-02-28 2016-05-17 Nestec S.A. Compositions and methods for inducing bone growth and inhibiting bone loss

Also Published As

Publication number Publication date
MX2011001733A (es) 2011-04-11
EP2320889A2 (en) 2011-05-18
RU2011109455A (ru) 2012-09-20
AU2009282482A1 (en) 2010-02-18
BRPI0917866A2 (pt) 2016-11-29
CN102300569A (zh) 2011-12-28
US20110165125A1 (en) 2011-07-07
CA2733907A1 (en) 2010-02-18
WO2010019212A2 (en) 2010-02-18
ZA201101934B (en) 2013-03-27
CA2733907C (en) 2019-03-12
JP2012504554A (ja) 2012-02-23
WO2010019212A3 (en) 2016-03-24
RU2513133C2 (ru) 2014-04-20
EP2320889A4 (en) 2016-09-21
AU2009282482B2 (en) 2015-11-26
US8835490B2 (en) 2014-09-16

Similar Documents

Publication Publication Date Title
MX343326B (es) Metodos para mejorar el metabolismo energetico.
MY151018A (en) Use of nutritional compositions for preventing disorders
MY176679A (en) Use of nutritional compositions for preventing disorders
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MY155710A (en) Composition for regulating lipid metabolism
MY156243A (en) Treatment for diabetes in patients inappropriate for metformin therapy
IN2012DN02624A (es)
MX2010005909A (es) Combinacion de inhibidores de fosfatasa de proteina tirosina y hormona de crecimiento humana para el tratamiento de atrofia muscular y trastornos relacionados.
MX2010004074A (es) Combinacion 059.
IN2012DN00624A (es)
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
IN2012DN02018A (es)
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MX2012013787A (es) Composiciones y metodos para estimular magp-1 y mejorar la apariencia de la piel.
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
MX2009006672A (es) Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
EP2633052A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH THE INTERFERON 1-RELATED DEVELOPMENT REGULATOR (IFRD1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF IFRD1
EA200701995A1 (ru) Способы уменьшения кальцификации
MX348898B (es) Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
ZA200805731B (en) Compositions and method for promoting fat loss
MX2013011996A (es) Metodos para regular la expresion de genes de sirtuina.
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
MX2013006094A (es) Metodo para inhibir patogenos usando composicion nutricional.

Legal Events

Date Code Title Description
FG Grant or registration